MYLAN 2035 MYLAN 2035 (Topiramate (sprinkle) 15 mg)

Pill imprint MYLAN 2035 MYLAN 2035 has been identified as Topiramate (sprinkle) 15 mg.

Topiramate is used in the treatment of obesity; bipolar disorder; migraine prevention; fibromyalgia; trigeminal neuralgia (and more), and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 15 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for MYLAN 2035 MYLAN 2035

Topiramate (sprinkle) 15 mg MYLAN 2035 MYLAN 2035
Topiramate (sprinkle)
Imprint:
MYLAN 2035
MYLAN 2035
Strength:
15 mg
Color:
Pink
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Carbonic anhydrase inhibitor anticonvulsants
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Mylan Pharmaceuticals Inc.

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web5)